Abiraterone acetate for metastatic castration-sensitive prostate cancer
Shane A, Walter M
Record ID 32018002254
English
Original Title:
Abiraterone acetate for metastatic castrate sensitive prostate cancer
Authors' objectives:
Question:
1. What is the clinical effectiveness of abiraterone acetate combined with ADT for mCSPC?
2. What is the cost-effectiveness of abiraterone acetate combined with ADT for mCSPC?
Details
Project Status:
Completed
Year Published:
2021
URL for published report:
https://cadth.ca/sites/default/files/pdf/htis/2021/RD0060%20Abiraterone%20for%20Prostate%20Cancer%20Final.pdf
URL for additional information:
https://cadth.ca/abiraterone-acetate-metastatic-castrate-sensitive-prostate-cancer
English language abstract:
An English language summary is available
Publication Type:
Rapid Review
Country:
Canada
MeSH Terms
- Prostatic Neoplasms
- Prostatic Neoplasms, Castration-Resistant
- Abiraterone Acetate
- Androgen Antagonists
- Antineoplastic Agents
Keywords
- Prostate cancer
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
<p>Canadian Agency for Drugs and Technologies in Health (CADTH)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.